Advisorshares Psychedelics ETF

*Potentially incorrect data identified

PSIL
ETF Ticker

+19.63%

+9.88%

NYSE Arca Exchange

Equity

Global

Thematic

The Advisorshares Psychedelics ETF, PSIL_US, is an actively managed strategy providing exposure to Global, Thematic Equity. It is listed on the NYSE Arca Exchange and has assets under management of $56.3m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Sep 14, 2021. It has a net expense ratio of 68bps. (All data in USD as of Oct 15, 2026 unless stated.)

The investment strategy underpinning the actively managed AdvisorShares Psychedelics ETF focuses on listed equities and depositary receipts of companies developing or enabling psychedelic-derived therapeutics and adjacent neuropsychiatric platforms. The universe is global but functionally centered on issuers listed or traded on U.S. venues for liquidity and custody reliability. Security selection blends clinical/regulatory milestone mapping, balance-sheet durability to key catalysts, intellectual-property positioning, and partner/sponsor quality, with valuation anchored in staged probability-adjusted models and comparative cash runway analysis. Portfolio construction accepts small- and micro-cap concentration but controls single-name risk with tiered sizing, liquidity haircuts, and hard caps tied to average daily volume. Exposure is diversified across drug development, enabling technologies, and service infrastructure to reduce binary trial risk. Rebalancing is event-driven around data readouts and financing windows; positions are reduced or exited on adverse safety/efficacy signals, dilutive capital structures, or erosion of expected risk-adjusted returns relative to pipeline peers.

ETF Details

Key Facts

Issuer:
AdvisorShares
AUM:
$56.3m (as of Aug 31, 2026)
Net Expense Ratio:
68 bps
Inception Date:
Sep 14, 2021
Index:
Actively managed strategy
Dividend Frequency:
Semi-Annually

Trading

Ticker:
PSIL
Exchange:
NYSE Arca Exchange
ISIN:
US00768Y3624
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
Global
Theme:
Thematic
Economic Development:
Global Markets
1 Year Volatility:
39.77%
3 Year Volatility:
71.30%
5 Year Volatility:
61.85%

Performance

TTM Dividend Yield:
8.19% (verify with issuer)
1 Month Performance:
-16.16%
3 Month Performance:
-12.76%
6 Month Performance:
12.47%
1 Year Performance:
9.88%
3 Year Performance:
54.74%
5 Year Performance:
-73.33%
Investment Proposition

AdvisorShares Psychedelics ETF (PSIL) targets exposure to companies advancing psychedelic-based therapeutics and enabling infrastructure. The actively managed strategy seeks capital appreciation by investing primarily in biopharma, life-sciences tools and services, and healthcare platforms connected to research, development, manufacturing and delivery of psychedelic compounds and adjacent modalities. The philosophy recognizes the long, binary nature of clinical and regulatory pathways, using diversification across programs, mechanisms of action, and commercialization models to moderate single-asset risk while retaining upside to successful readouts and policy evolution. Style characteristics often lean toward early-stage growth with elevated idiosyncratic risk, tempered by allocations to ecosystem providers that may exhibit steadier revenues. Potential roles include a thematic satellite within healthcare/biotech, a calculated innovation sleeve for return asymmetry, or a tactical vehicle for investors anticipating constructive clinical or regulatory milestones. The segment may be favored when funding windows open and sentiment improves toward novel neuropsychiatric treatments, and can be challenged during risk-off regimes or trial setbacks. A key risk to monitor is regulatory and reimbursement uncertainty, which can materially alter timelines and valuations across the opportunity set.

ETF Analytics

Fund Discovery

4 Suggestions